Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on March 3, 2014, regarding an event that occurred on February 26, 2014. The filing discloses the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Mark P. Carthy as a director, effective February 26, 2014. His term will last until the 2014 annual meeting of stockholders or until his successor is elected. Mr. Carthy brings significant experience in healthcare venture capital and biotechnology, having previously served as Managing Partner of Orion Equity Partners, LLC, and held executive roles at Cubist Pharmaceuticals and Vertex Pharmaceuticals.
Compensation and Governance
Consistent with the Company's policy for non-employee directors, Mr. Carthy's compensation package includes:
- A pro-rated annual retainer of $6,667.
- An additional $2,000 fee per in-person Board meeting.
- An additional $500 fee per telephonic Board meeting.
- 20,000 options to purchase shares of the Company's common stock.
Investor Verification Checklist
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., as the input metadata referenced Opus Genetics, Inc.
- Confirm the effective date of the director appointment (February 26, 2014).
- Review the specific terms of the stock option grant (20,000 options) in the Company's equity incentive plan.
- Check for any subsequent filings regarding the 2014 annual meeting of stockholders to confirm the duration of the appointment.